- Home
- ZURA vs REFI Comparison
ZURA vs REFI Comparison
Compare ZURA & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | REFI |
|---|---|---|
| Founded | 2022 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 278.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZURA | REFI |
|---|---|---|
| Price | $4.45 | $11.24 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 153.0K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.79% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | N/A | ★ $48,857,628.00 |
| Revenue This Year | N/A | $17.47 |
| Revenue Next Year | N/A | $0.06 |
| P/E Ratio | ★ N/A | $19.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.01 | $9.69 |
| 52 Week High | $7.25 | $13.49 |
Technical Indicators
Market Signals| Indicator | ZURA | REFI |
|---|---|---|
| Relative Strength Index (RSI) | 30.44 | 68.40 |
| Support Level | $4.22 | $10.96 |
| Resistance Level | $5.94 | $11.55 |
| Average True Range (ATR) | 0.37 | 0.20 |
| MACD | -0.17 | 0.03 |
| Stochastic Oscillator | 4.03 | 83.33 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.